Journal Article

Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients

Rehman, Irshad Ur, Yasmin, Humaira, Khan, Muhammad Ajmal, Ullah, Amin, Butt, Sadia, Ahmad, Jamshaid, Gohar, Maryam, Ahmad, Ajaz

2023

Overview

Several nucleotide analogues have been approved for use in treating hepatitis B virus (HBV) infection. Long-term exposure to therapy leads to the emergence of mutations within the HBV DNA polymerase gene, resulting in drug resistance, a major factor contributing to therapy failure. Chronic HBV patients from the Khyber Pakhtunkhwa province, Pakistan, who had completed 6 months of therapy participated in this study. Samples were collected from 60 patients. In this study, the entire reverse transcriptase domain of the HBV polymerase gene was amplified using nested polymerase chain reaction and sequenced. Drug-resistant mutations were detected in nine (22.5%) patients. All of these patients had lamivudine-resistant mutations (rtM204V + L180M), while seven individuals (17.5%) had both lamivudine- plus entecavir-resistant mutations (L180M + M204V + S202G). N236T, a mutation that gives rise to tenofovir and adefovir resistance, was observed in two (5%) patients. T184A, a partial drug-resistant mutation to entecavir, was found in five (12.5%) patients. Furthermore, other genotypic variants (100%) and vaccine escape mutations (5%) were additionally observed. Moreover, pN459Y (35%), pN131D (20%), pL231S (20%), pP130Q (17.5%), pS189Q (12.5%), pP161S (5%), pH160P (2.5%), pT322S (2.5%), and pA223S (2.5%) mutations in the polymerase gene, as well as sA166V (17.5%), sQ181K (12.5%), sV184R (7.5%), sA17E (5%), sP153S/K (5%), sW156C (5%), sC76Y (2.5%), and S132F (2.5%) mutations in the small surface gene, were identified for the first time in this study. Phylogenetic analysis showed that genotype D was predominant amongst the HBV carriers. Subtype D1 was found in most patients, while two patients were subtype D9. These novel findings may contribute to the body of knowledge and have clinical significance for treating and curing HBV infections in Pakistan.

• Publisher: MDPI AG
• Subject: Adefovir / Antigens / chronic exposure / Diagnosis / Disease resistance / DNA polymerase / DNA-directed DNA polymerase / Drug resistance / Drug therapy / Gene amplification / Gene mutations / genes / Genetic aspects / Genomes / Genomics / genotype / Genotype & phenotype / Genotypes / Health aspects / Hepatitis / Hepatitis B / Hepatitis B virus / Identification and classification / Infections / Lamivudine / Mutation / mutations / Nucleoside analogs / nucleosides / Nucleotide analogs / Nucleotides / Pakistan / Patients / phylogenetic analysis / Phylogenetics / Phylogeny / Polymerase chain reaction / polymerase gene / Proteins / RNA-directed DNA polymerase / Statistical analysis / surface gene / Tenofovir / therapeutics / Therapy / vaccines